# Kymera Therapeutics (KYMR) — News

KYMR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/kymr/news

## Recent headlines

- [Kymathera reports $80M Series B financing](https://www.ainvest.com/news/kymathera-reports-80m-series-financing-2610) — AInvest Wire, Oct 6, 2026
  Kymera Therapeutics, Inc. has announced the completion of an $80 million Series B financing round, marking a significant milestone for the biotechnology company. The funding is expected to advance the company’s pipeline of therapeutic candidates and support ongoing research and development…
- [Kymera Therapeutics, Inc.: Citigroup raises target price to $150 from $135](https://www.ainvest.com/news/kymera-therapeutics-citigroup-raises-target-price-150-135-2610) — AInvest Wire, Oct 5, 2026
  Kymera Therapeutics, Inc. (KYMR) has seen recent analyst activity, with Citigroup raising its price target for the stock to $150 from $135, reflecting increased confidence in the company’s prospects. This adjustment follows a series of analyst actions, including BofA Securities raising its target…
- [Kymera gets upside 90-day catalyst watch at Cit](https://www.ainvest.com/news/kymera-upside-90-day-catalyst-watch-cit-2610) — AInvest Wire, Oct 5, 2026
  Kymera Therapeutics (NASDAQ: KYMR) has been placed on Citi’s "upside 90-day catalyst watch," indicating that the firm is monitoring the biopharmaceutical company for potential near-term developments that could positively impact its stock performance. This designation typically reflects expectations…
- [Kymera Therapeutics, Inc.: Stifel raises target price to $152 from $132](https://www.ainvest.com/news/kymera-therapeutics-stifel-raises-target-price-152-132-2609) — AInvest Wire, Sep 22, 2026
  Stifel has revised its price target for Kymera Therapeutics, Inc. (KYMR), raising it to $152 from $132, reflecting updated expectations for the company’s financial performance and strategic outlook. The adjustment follows a recent analysis of Kymera’s business operations and market positioning. The…
- [Kymera Therapeutics, Inc.: JP Morgan raises target price to $140 from $121](https://www.ainvest.com/news/kymera-therapeutics-jp-morgan-raises-target-price-140-121-2609) — AInvest Wire, Sep 2, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).